Terms: = Endocrine gland cancer AND RSPO3, Q9BXY4, THSD2, PWTSR, FLJ14440, CRISTIN1, ENSG00000146374, 84870
5 results:
1. The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand-dependent cancer Models.
Phillips C; Bhamra I; Eagle C; Flanagan E; Armer R; Jones CD; Bingham M; Calcraft P; Edmenson Cook A; Thompson B; Woodcock SA
Cancer Res Commun; 2022 Sep; 2(9):914-928. PubMed ID: 36922934
[TBL] [Abstract] [Full Text] [Related]
2. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
Guo B; Wang Y; Liu W; Zhang S
Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
[TBL] [Abstract] [Full Text] [Related]
3. Multi-genomic analysis of 260 adrenocortical cancer patient tumors identifies novel network BIRC5-hsa-miR-335-5p-PAX8-AS1 strongly associated with poor survival.
Subramanian C; McCallister R; Cohen MS
Surgery; 2023 Jan; 173(1):43-51. PubMed ID: 36202651
[TBL] [Abstract] [Full Text] [Related]
4. Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.
Boone JD; Arend RC; Johnston BE; Cooper SJ; Gilchrist SA; Oelschlager DK; Grizzle WE; McGwin G; Gangrade A; Straughn JM; Buchsbaum DJ
Lab Invest; 2016 Feb; 96(2):249-59. PubMed ID: 26658453
[TBL] [Abstract] [Full Text] [Related]
5. Monozygotic twins discordant for constitutive BRCA1 promoter methylation, childhood cancer and secondary cancer.
Galetzka D; Hansmann T; El Hajj N; Weis E; Irmscher B; Ludwig M; Schneider-Rätzke B; Kohlschmidt N; Beyer V; Bartsch O; Zechner U; Spix C; Haaf T
Epigenetics; 2012 Jan; 7(1):47-54. PubMed ID: 22207351
[TBL] [Abstract] [Full Text] [Related]
